Milvexian Fails to Reduce CV Events After ACS

MUNICH — Adding the investigational factor XIa inhibitor milvexian to standard antiplatelet therapy did not reduce cardiovascular (CV) events after acute coronary syndrome (ACS), despite evidence that the drug was exerting its expected pharmacodynamic effect, according to the phase 3 LIBREXIA ACS trial. The trial was stopped early for futility in November 2025 after a …

Milvexian Fails to Reduce CV Events After ACS

Leave a ReplyCancel reply

US trade war: What if Russian oil is excluded from markets? Envoy Alipov warns ‘world will not cope’

Hostess’ push into breakfast pastries has sent its stock soaring — and UBS says the gains are just getting started

UK recognises India’s carbon credit scheme under CBAM, easing tax burden for exporters

Six Years Later, the Number of Bitcoin ATMs Just Crossed 5,000 Globally

Cognition AI raises $2 billion at $48 billion valuation

This forgotten investigation into Microsoft, 10 years before the antitrust trial, let it get away with tactics that sealed its tech dominance, according to a key player

Big Brands Have Money. Challenger Brands Have an Edge.

Leaked Wayfair documents reveal massive race disparity in company leadership as it grapples with employee-led crisis over furnishing border camps

With the copper price surfing all-time highs, here’s what one CEO thinks about the sector long term

Air India flight from Mumbai to New York makes emergency landing in London after reported bomb threat

Study finds limited evidence for helping hospitalized patients with alcohol use disorder connect to follow-up care

Study finds social, financial and health care factors shape resilience in adults with sickle cell disease

Researchers identify risk factors for dementia among American Indians

A NY Hospital Tried To Close Its Birthing Center. This City United To Fight Back.

Nonprofits Are Helping Musicians Pay for Insurance in Austin, Texas, and Beyond